PE AI Diligence & IC Scorecard Workbench
CONFIDENTIAL — INVESTMENT COMMITTEE TECHNICAL DILIGENCE MEMORANDUM DATE: NOV 18, 2026 | PRINCIPAL-LED AUDIT

Apex Clinical Coding AI

Sector: B2B Healthcare SaaS • Mandate: Confirmatory Tech Diligence • Baseline ARR: $48.0M
AI Readiness Index
56 / 100
VALUATION RE-TRADE RECOMMENDED
Executive Investment Committee Synthesis

At projected 4.0x hold-period workflow volume, uncalibrated frontier inference spend expands from $1.30M/yr to $5.18M/yr—creating $3.89M in unbudgeted annual compute drag and eroding gross margins by -405 bps. Deploying a deterministic control plane and semantic caching in the First 100 Days recovers $3.01M/yr in EBITDA while eliminating shared Non-Human Identity (NHI) breach exposure.

Unbudgeted Scale Compute Drag
$3.89M/yr
Run-rate rises $1.30M → $5.18M
Gross Margin Erosion → Recovery
-405 bps
+313 bps recovered via routing
Est. 100-Day Remediation Budget
$185K
Payback: 0.7 mos at scale run-rate
Hold-Period Unit Economics & Gross Margin Trajectory
Management Reported Baseline (%)
Unmitigated “Intelligence Tax” Trajectory (%)
Agentic Path Hardened Control Plane (%)
Technical Diligence Pillar Assessment
Diligence Pillar Rating Current Target Posture Agentic Path Group Intervention
Fiduciary Tail-Risk & Red-Flag Findings

Deal-Team Scoping Note: Target markets "autonomous clinical coding" at 76% gross margin, but inference routing relies on uncached frontier models.

Post-Close 100-Day Remediation & Margin Expansion Plan
Copied IC Memorandum summary to clipboard.